Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Links shared publicly online about this topic.
- 0total visits
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Press Release Content
View full resource at businesswire.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Phase 3 Clinical Trial, Avonex, Rebif
Most Recently Shared on October 22, 2011 at 1:27 pm By:
Alemtuzumab Significantly Reduces Relapses in #MS versus Interferon Beta-1a in a Phase 3 Study #ECTRIMS2011 http://t.co/7iVePsGM
Advertisement
